Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Announcement under Regulation 30 (LODR)-Press Release / Media Release

 We wish to inform that the USFDA inspected the injectables manufacturing facility of Liva Pharmaceuticals Ltd. (Liva) which is located at Vadodara, from 20th August 2018 to 28th August 2018. Liva is a 100% subsidiary of Cadila Healthcare Ltd. This was a product specific Pre Approval Inspection. The inspection concluded with 5 observations. Liva will respond to the USFDA within 15 days. It may be noted that at present Liva does not export any products to the US market.
29-08-2018
Bigul

Cadila Healthcare's Biologics facility completes USFDA inspection

 Cadila Healthcare has informed the exchanges that the US Food and Drug Administration (FDA) has inspected the drug maker's biologics manufacturing fac
24-08-2018
Bigul

Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Cadila Healthcare's Biologics manufacturing facility successfully completes USFDA inspection.
24-08-2018
Bigul

Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

 Cadila Healthcare Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
14-08-2018
Bigul

Growth worries ahead for Cadila Healthcare after Q1 estimate miss

 With mega products in US facing rising competition, analysts watchful on new launches
14-08-2018
Bigul

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

 Announcement of results by the Chairman along with the Scrutinizer''s Consolidated Report.
13-08-2018
Bigul

Shareholder Meeting / Postal Ballot-Outcome of AGM

 Proceedings of Twenty Third Annual General Meeting of Cadila Healthcare Limited held today i.e. August 13, 2018.
13-08-2018
Bigul

Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Cadila Healthcare acquires 51% stake in Windlas Healthcare
13-08-2018
Bigul

Announcement under Regulation 30 (LODR)-Acquisition

 The Company has entered into an agreement to invest in the equity shares of Windlass Healthcare Private Limited (Windlass), for acquiring 51% share capital of Windlass. The details as required under regulation 30 of the SEBI Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is annexed at Annexure A to this letter.
13-08-2018
Bigul

Results For The Quarter Ended On June 30, 2018.

 Results for the quarter ended on June 30, 2018.
13-08-2018
Next Page
Close

Let's Open Free Demat Account